The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir. Here we determined whether raltegravir was a substrate for ABCB1 or the influx transporters SLCO1A2, SLCO1B1, SLCO1B3, SLC22A1, SLC22A6, SLC10A1, SLC15A1, and SLC15A2. Raltegravir transport by ABCB1 was studied with CEM, CEM VBL100 , and Caco-2 cells. Transport by uptake transporters was assessed by using a Xenopus laevis oocyte expression system, peripheral blood mononuclear cells, and primary renal cells. The kinetics of raltegravir transport and competition between raltegravir and tenofovir were also investigated using SLC22A6-expressing oocytes. Raltegravir was confirmed to be an ABCB1 substrate in CEM, CEM VBL100 , and Caco-2 cells. Raltegravir was also transported by SLC22A6 and SLC15A1 in oocyte expression systems but not by other transporters studied. The K m and V max for SLC22A6 transport were 150 M and 36 pmol/oocyte/h, respectively. Tenofovir and raltegravir competed for SLC22A6 transport in a concentrationdependent manner. Raltegravir inhibited 1 M tenofovir with a 50% inhibitory concentration (IC 50 ) of 14.0 M, and tenofovir inhibited 1 M raltegravir with an IC 50 of 27.3 M. Raltegravir concentrations were not altered by transporter inhibitors in peripheral blood mononuclear cells or primary renal cells. Raltegravir is a substrate for SLC22A6 and SLC15A1 in the oocyte expression system. However, transport was limited compared to endogenous controls, and these transporters are unlikely to have a great impact on raltegravir pharmacokinetics.
HIV infection and AIDS continue to be a major cause of worldwide mortality in the 21st century. A UNAIDS/WHO report in 2009 estimated that 33.4 million people worldwide were infected with HIV in 2008, with AIDS-related deaths numbering 2 million. Recent attempts to develop a vaccine for HIV have been largely unsuccessful (18) . This, combined with increasing drug resistance, has emphasized the need to develop new drugs with unique mechanisms of action.
Raltegravir represents a new class of antiretroviral treatment (8) , targeting the HIV-1 integrase enzyme by binding to the active site and preventing viral DNA insertion into the host genome (11) . Recent trials have shown raltegravir to have a sustained antiretroviral effect and good tolerability in treatment-experienced HIV-1 patients (33) . The primary route of raltegravir metabolism is glucuronidation via UGT1A1, and raltegravir is not a substrate or an inhibitor of the major cytochrome P450 enzymes (19, 24) . However, the involvement of human drug transporters in raltegravir absorption, disposition, metabolism, and excretion (ADME) has not been fully investigated. Raltegravir has been described as being an ABCB1 substrate (25) , but there are no data yet in the public domain. Raltegravir has shown higher concentrations (1.7-fold) in semen (4) and lower concentrations (0.04-to 0.39-fold) in cerebrospinal fluid (7, 41) than in plasma, which may be facilitated by drug transporters present at membrane barriers.
There are important reasons why raltegravir should be screened for potential transport by known drug transporters. First, by regulating intracellular permeation, drug transporters could be an important factor in an understanding of the lack of a clear pharmacokinetic-pharmacodynamic (PK-PD) relationship of raltegravir, i.e., the similar virological response observed for patients given a wide range of raltegravir doses (29) . Second, a knowledge of the mechanisms that control raltegravir disposition may help rationalize or even anticipate drugdrug interactions in the clinic. Since raltegravir represents the first member of a new drug class, possessing a unique chemical structure containing a diketo acid derivative (34) , class-specific trends in drug transport may be evident, such as those reported previously for protease inhibitors with ABCB1 (26, 37) or nucleoside reverse transcriptase inhibitors with organic anion and cation transporters (35, 36) . Finally, knowledge of which transporters are involved in raltegravir ADME will identify candidate genes for future pharmacogenetic studies.
There have been a number of studies undertaken to evaluate the pharmacokinetic interactions between raltegravir and coadministered drugs. Most studies have shown raltegravir metabolism and disposition to be largely unaffected. For example, etravirine (1) , maraviroc (3), darunavir (2) , and rifabutin (6) had no or a relatively modest effect on raltegravir plasma concentrations. In addition, despite ritonavir being an inducer of both ABCB1 (9) and UGT1A1 (12) , the drug caused only a minimal reduction in the raltegravir plasma concentration (22) . Similarly, tipranavir combined with ritonavir had little impact on raltegravir pharmacokinetics (13) . However, there are interactions between raltegravir and coadministered drugs that have a more marked effect on raltegravir disposition.
Atazanavir is an inhibitor of UGT1A1 (42) , and the coadministration of atazanavir (400 mg once a day [QD]) with raltegravir (100 mg single dose) resulted in increased raltegravir plasma area under the concentration-time curve (AUC), C max , and C min values of 72%, 53%, and 95%, respectively (20) . This interaction was also confirmed in a separate study (43) . Efavirenz and rifampin are inducers of UGT1A1 expression (14, 40) and have been shown to decrease raltegravir plasma exposure (22, 39) . Other interactions were reported previously for omeprazole (21) and fosamprenavir (28) .
One intriguing interaction is that of tenofovir, causing a moderate increase in the raltegravir AUC and C max by 49% and 64%, respectively (38) . Although the increase in the raltegravir plasma concentration is unlikely to have any important clinical significance (i.e., no increase in toxicity), the mechanism of the interaction is currently unexplained. Interestingly, tenofovir is an anionic compound when charged and is therefore a substrate of the organic anion uptake transporters SLC22A6 and SLC22A8 (36) .
The aim of this study was to confirm the transport of raltegravir by ABCB1 (phosphoglycoprotein) and to investigate potential transport by major human drug influx transporters (25) , with the exception of CNTs (concentrative nucleoside transporters) and ENTs (equilibrative nucleoside transporters), since these are specific to nucleotides. The influx transporters characterized were SLCO1A2 (OATPA), SLCO1B1 (OATPC), SLCO1B3 (OATP8), SLC22A1 (OCT1), SLC22A6 (OAT1), SLC10A1 (NTCP), SLC15A1 (PEPT1), and SLC15A2 (PEPT2). Since tenofovir is a substrate for SLC22A6, the putative role for this transporter in the interaction between raltegravir and tenofovir was also investigated. 2 ). Primary renal proximal tubule epithelial cells were maintained in cell culture by passage at 95% confluence using renal epithelial cell basal medium with essential components (0.5% [wt/vol] FCS, 10 nM triiodothyronine, 10 ng/ml recombinant human epidermal growth factor [rhEGF], 100 ng/ml hydrocortisone hemisuccinate, 5 g/ml rh insulin, 1 M epinephrine, 5 g/ml transferrin, 2.4 mM L-alanyl-L-glutamine) prior to the experiment (37°C in 5% CO 2 ).
MATERIALS AND METHODS

Chemical
Cytotoxicity testing. CEM and Caco-2 cell lines (100 l; 2 ϫ 10 5 cells/ml) were incubated in a 96-well Nunc flat-bottom plate (37°C in 5% CO 2 for 120 h) with 0, 0.001, 0.01, 0.1, 1, 10, and 100 M raltegravir. To validate the study, the cytotoxic control compounds epirubicin and vinblastine were incubated (0.1, 1, 10, and 100 M) with CEM and Caco-2 cells, respectively. Following incubation, the plates were centrifuged (2,000 rpm for 5 min), and the supernatant was discarded and replaced with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (1 mg/ml MTT, 100 l Hanks balanced salt solution [HBSS]). A standard MTT assay was performed, the mean absorption was calculated for each raltegravir concentration (n ϭ 6), and results were expressed as the percent absorbance compared to the vehicle control (30) .
Confirmation of ABCB1 expression in CEM and CEM VBL100 cells by flow cytometry. The expression of ABCB1 in CEM and CEM VBL100 cells was determined by using a Coulter Epics XL-MCL flow cytometer as previously described (27) . Results are given as relative fluorescence units (mean fluorescence minus that of the isotype control; n ϭ 3) Ϯ standard deviations (SD).
Cellular accumulation of raltegravir in CEM and CEM VBL100 cells. CEM and CEM VBL100 cells of a constant cell density (1 ml; 2.5 ϫ 10 6 cells/ml) were incubated (37°C in 5% CO 2 containing the potent noncompetitive ABCB1 inhibitor tariquidar (300 nM for 30 min), which was also included during the 30 min of substrate incubation. Following incubation, the cells were centrifuged (2,000 rpm at 1°C for 1 min), and 100 l supernatant aliquots were taken and added to scintillation vials in order to calculate extracellular drug concentrations. The remaining supernatant was discarded, and the cells were washed with ice-cold HBSS and centrifuged (2,000 rpm at 1°C for 1 min). This HBSS wash was repeated a total of 3 times, after which the HBSS was discarded and 100 l tap water was added to lyse the cells. The incubations were vortexed for 5 min, and 100 l samples were added to scintillation vials. Four milliliters of scintillation fluid was added to all the scintillation vials, which were then loaded into a liquid scintillation analyzer (Tri-Carb). Using supernatant and intracellular radioactivity readings, cellular accumulation ratios (CARs) (ratio of drug in the cell pellet compared with drug in the supernatant, assuming a 1 pl volume per cell) were calculated for raltegravir and saquinavir in each cell line as described previously (23) .
Bidirectional transport of raltegravir using Caco-2 cell monolayers. Caco-2 monolayer experiments were performed as previously described (17), with slight modifications. When confluent, Caco-2 cells (passage 30) were seeded onto polycarbonate membrane transwells at a density of 5 ϫ 10 5 cells/cm 2 . The medium was replaced every 2 days, and plates were used in the experiments after 21 days. Monolayer integrity was checked by using a MillicellERS instrument (Millipore) to determine the transepithelial electrical resistance (TEER) across the monolayer. A TEER of Ͼ600 was deemed acceptable. On the day of the experiment, the TEER was assessed, and the medium in each plate was replaced with warm transport buffer (HBSS containing 25 mM HEPES and 0.1% [wt/vol] bovine serum albumin [pH 7.4]) and allowed to equilibrate (37°C for 30 min). For inhibition studies this transport buffer contained tariquidar (300 nM). The transport buffer in the apical (for apical-to-basolateral transport) and basolateral (for basolateral-to-apical transport) sides was replaced with transport buffer containing either the test substrate [ where dQ/dt is the change in the drug concentration in the receiver chamber over time (nM/s), v is the volume in the receiver compartment (ml), A is the total surface area of the transwell membrane (cm 2 ), C 0 is the initial drug concentration in the donor compartment (nM), and P app is the apparent permeability (cm/s).
Production of uptake transporter cRNA for Xenopus laevis oocyte injection. SLCO1A2, SLCO1B1, and SLCO1B3 were cloned from cDNA extracted from Huh-7D12 and A549 cells as described previously (15) . IMAGE clones were linearized and used as a template in cRNA production by using an mMessage mMachine RNA transcription kit (Ambion) according to the manufacturer's protocol. SLC10A1, SLC15A1, and SLC15A2 cRNAs were provided by Becton Dickinson (Oxford, United Kingdom).
X. laevis oocyte isolation, collagenase treatment, and microinjection. Oocytes were harvested from sacrificed adult female X. laevis frogs and treated with modified Barth's solution minus calcium (88 mM NaCl, 1 mM KCl, 15 mM HEPES, 100 U penicillin, 100 g streptomycin [pH 7.4]) containing collagenase (1 mg/ml at 22°C in a 60-rpm shaker for 1 h). Cells were washed and transferred into Barth's solution containing calcium (88 mM NaCl, 1 mM KCl, 15 mM HEPES, 0.3 mM CaCNO 3 ⅐ 6H 2 O, 41 M CaCl 2 ⅐ 6H 2 O, 0.82 mM MgSO 4 ⅐ 7H 2 O, 100 U penicillin, 100 g streptomycin [pH 7.4]) and stored in a cold room at 8°C. Healthy cells were selected and injected with transporter cRNA (50 ng per oocyte; 1 ng/nl) or sterile water (50 nl) and maintained in Barth's solution containing calcium to allow transporter expression (5 days for SLCO1B3-injected oocytes and 3 days for all other conditions; 18°C). Barth's solution was replaced daily, and damaged oocytes were removed.
Drug accumulation in transporter RNA-injected X. laevis oocytes. Drug accumulation studies using X. laevis oocytes were performed as described previously, with slight modifications (15) . Unless otherwise stated, radiolabeled drug was incubated in Hanks balanced salt solution (pH 7.4) with Ն4 oocytes per condition in a 48-well Nunc flat-bottom plate (500 l; 0.33 Ci/ml; 1 M; room temperature in a 60-rpm shaker for 1 h). Radiolabeled positive-control drugs were tested alongside [ C]tetraethyl ammonium for SLC22A1. All incubations were terminated by transferring the oocytes into cell strainers and washing them in ice-cold HBSS to remove extracellular drug. Each oocyte was placed into a separate scintillation vial followed by treatment with 100 l 10% SDS. After the disintegration of the oocytes by the SDS treatment, 4 ml scintillation fluid was added to all vials, which were then loaded into a liquid scintillation analyzer (Tri-Carb). Results are expressed as the amount of drug per oocyte (pmol/oocyte), assuming that each oocyte had a volume of 1 l (15). Results were obtained using oocytes from Ն2 X. laevis frogs.
Determination of raltegravir and tenofovir K m and V max using SLC22A6-injected oocytes. The time-dependent SLC22A6-mediated transport of [ H]raltegravir (0.33 Ci/ml; 1 M) was also incubated with H 2 Oinjected cells with and without 300 M tenofovir in order to confirm the role of SLC22A6. This experiment was repeated using [ 3 H]tenofovir as the substrate and nonradiolabeled raltegravir as the competitor drug using the same concentration range and was terminated as described above. Fifty percent inhibitory concentrations (IC 50 ) were generated for both drugs by using Prism 3.0.
Isolation of peripheral blood mononuclear cells from human blood. Venous blood samples (60 ml) were obtained from healthy volunteers via venipuncture. Blood was layered onto Ficoll-Paque Plus, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation according to the manufacturer's protocol. Cells were washed with ice-cold HBSS and centrifuged (800 ϫ g at 1°C for 5 min). This HBSS wash was repeated a total of 3 times, after which the HBSS was discarded and cells were resuspended in RPMI 1640 medium (10% [wt/vol] FCS) for use in experiments.
Cellular accumulation of raltegravir in peripheral blood mononuclear cells. The accumulation of raltegravir in peripheral blood mononuclear cells was determined by using the same method as that used with CEM and CEM VBL cells, with slight modifications. Briefly, cells of a constant cell density (1 ml; 5 ϫ 10 6 cells/ml) were incubated (37°C in 5% CO 2 H]tenofovir (1 M; 0.6 Ci/ml) with 100 M raltegravir (3 h at 37°C in 5% CO 2 ). Once incubation was complete, an extracellular sample was taken, and incubations were terminated by washing each well with cold HBSS (4°C; 3 ml) three times to remove excess drug. Cells were lysed with 0.5 ml tap water, and contents were analyzed by liquid scintillation as described above for the CEM experiments.
Determination of transporter mRNA expression in primary renal proximal tubule cells and whole kidney. mRNA from primary renal proximal tubule cells were isolated by using Tri reagent according to the manufacturer's protocol. mRNA was then reverse transcribed by using the TaqMan reverse transcription kit according to the manufacturer's protocol. Real-time PCR using TaqMan array plates was combined with cDNA (40 ng) and used to quantify mRNA expression by standard methodologies. This process was repeated, and mRNA quantification was obtained for whole kidneys purchased from Ambion (United Kingdom), which was created from a pool of three individuals. Transporters were quantified by using the ⌬⌬C T method and included SLC22A6, SLC22A1, SLC22A2, SLC22A3, ABCC1, ABCC2, ABCC3, ABCC4, and ABCC10. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene.
Statistical analysis. Data were analyzed by using SPSS 13.0 for Windows. All data were tested for normality by using the Shapiro-Wilk test. An independent t test was used to determine the significance of the ABCB1 flow cytometry data, Caco-2 transwell data, PBMC accumulation data, and renal cell accumulation data. The Mann-Whitney U test was used for all other data. A two-tailed P value of Ͻ0.05 was accepted as being statistically significant.
RESULTS
Toxicity of raltegravir in CEM and Caco-2 cell lines. Raltegravir was not cytotoxic in CEM or Caco-2 cell lines at the tested concentrations. Cell viability (percent mean viability compared to the drug-free control Ϯ SD; n ϭ 6) was unaffected by concentrations of up to 100 M in the Caco-2 (104.9% Ϯ 12.7%) and CEM (113.9% Ϯ 13.0%) cell lines. A concentration of 1 M raltegravir was used in subsequent experiments with these cells to minimize the risk of transporter saturation, as previously recommended (17) . ABCB1 expression levels in CEM and CEM VBL100 cell lines. The expression of ABCB1 in CEM and CEM VBL100 cell lines was determined by using flow cytometry. CEM VBL100 cells had a significantly higher level of ABCB1 cell surface expression (relative fluorescence ϭ 246.7 Ϯ 9.3; P Ͻ 0.001) than in CEM cells (relative fluorescence ϭ 1.5 Ϯ 0.5).
Effect of the ABCB1 inhibitor tariquidar on the accumulation of raltegravir and saquinavir using CEM and CEM VBL100 cell lines. The cellular accumulation of [ 3 H]raltegravir was determined with CEM and ABCB1-overexpressing CEM VBL100 cells, and the effect of the ABCB1 inhibitor tariquidar on this accumulation was investigated (Fig. 1A) . The level of (Fig. 1B) . This difference was also reversed when CEM VBL100 cells were treated with tariquidar (CAR ϭ 37.8 Ϯ 8.5).
Effect of the ABCB1 inhibitor tariquidar on the bidirectional transport of raltegravir and digoxin using a Caco-2 monolayer. Determination of the time-dependent accumulation of raltegravir, tenofovir, and aminohippuric acid in SLC22A6-injected oocytes. All drugs tested had a greater accumulation rate in SLC22A6-injected oocytes than in H 2 O-injected oocytes ( Fig. 2A, B, and C) . [ 3 H]raltegravir concentrations continued to increase in SLC22A6-injected oocytes throughout the 4-h incubation period, whereas saturation was reached in H 2 O-injected oocytes after 2 h. Both Determination of raltegravir and tenofovir K m and V max values using SLC22A6-injected oocytes. An incubation time of 1 h was chosen for subsequent kinetic studies. [ 3 H]raltegravir and [
3 H]tenofovir kinetics were determined for SLC22A6 in the oocyte expression system (Fig. 2D and E) . The raltegravir K m and V max were calculated to be 150 M and 36 pmol/ oocyte/h, respectively. The raltegravir CL int (V max /K m ) was calculated to be 0.2 l/oocyte/h. The tenofovir K m and V max were calculated to be 25 M and 129 pmol/oocyte/h, respectively. The tenofovir CL int was calculated to be 5.2 l/oocyte/h.
Competition between raltegravir and tenofovir for SLC22A6 transport. When incubated at 1 M for 1 h, [ 3 H]raltegravir showed a significantly higher level of accumulation in SLC22A6-injected oocytes than in H 2 O-injected oocytes (1.73 Ϯ 0.46 pmol/oocyte versus 0.54 Ϯ 0.06 pmol/oocyte; n ϭ 5; P ϭ 0.014) (Fig. 3A) . The coincubation of [ 3 H]raltegravir with 1, 3, 10, 30, 100, and 300 M tenofovir resulted in levels of [ 3 H]raltegravir accumulation in SLC22A6-injected oocytes of 1.78 Ϯ 0.41 pmol/oocyte, 1.63 Ϯ 0.62 pmol/oocyte, 1.48 Ϯ 0.58 pmol/oocyte, 1.28 Ϯ 0.27 pmol/oocyte, 0.96 Ϯ 0.28 pmol/oocyte, and 0.83 Ϯ 0.31 pmol/oocyte, respectively (Fig.  3C ). There was a statistically significant decrease (P Ͻ 0.05) in the level of [ 3 H]raltegravir accumulation when concentrations of 100 M tenofovir and higher were added to the incubation mixture.
Similar results were seen when [ 3 H]tenofovir accumulation was investigated in the presence of various concentrations of raltegravir. When incubated at 1 M for 1 h, [ 3 H]tenofovir showed a significantly higher level of accumulation in SLC22A6-injected oocytes than in H 2 O-injected oocytes (2.11 Ϯ 0.37 pmol/oocyte versus 0.03 Ϯ 0.01 pmol/oocyte; n ϭ 5; P Ͻ 0.009) (Fig. 3B) . The coincubation of Transporter expression in primary renal proximal tubule cells versus whole kidneys. All transporters tested showed lower or undetectable levels of expression in primary renal proximal tubule cells compared to whole kidney (Fig. 4E) . Importantly, SLC22A6 was undetectable in primary renal cells.
DISCUSSION
The results from CEM/CEM VBL accumulation and Caco-2 bidirectional transport experiments confirm that raltegravir is transported by ABCB1. The extent of raltegravir transport by ABCB1 was small compared to the transport of the positive controls saquinavir and digoxin. Indeed, FDA guidelines recommend that a drug should achieve an efflux ratio of at least 2 in Caco-2 cell monolayers and show greater than a 50% reduction in the efflux ratio when an ABCB1 inhibitor is used in order for ABCB1 transport to be considered relevant in vivo (16) . In our Caco-2 experiment raltegravir achieved an efflux ratio of only 1.9 and a reduction of 32% when tariquidar was used to inhibit ABCB1. The low rate of raltegravir transport by ABCB1 may explain the absence of major drug interactions with known potent ABCB1 inhibitors. This is consistent with a on June 29, 2017 by guest http://aac.asm.org/ previous report that the coadministration of low-dose ritonavir had no major effect on raltegravir pharmacokinetics, and no dose adjustment is required for patients (22) . Raltegravir showed significantly increased levels of accumulation in SLC15A1-and SLC22A6-injected oocytes compared to H 2 O-injected controls, but accumulation was not higher in oocytes expressing SLCO1A2, SLCO1B1, SLCO1B3, SLC15A2, and SLC10A1. In SLC22A6-injected oocytes, both raltegravir and tenofovir inhibited the accumulation of the other in a concentration-dependent manner (Fig. 3C and D) . No competition was observed for H 2 O-injected oocytes, which supports the hypothesis that raltegravir and tenofovir are competing for SLC22A6 transport and are not having nonspecific effects on oocyte membrane permeability. IC 50 values of 27.3 M and 14.0 M were determined for tenofovir and raltegravir, respectively. The IC 50 obtained for raltegravir was much lower than the observed K m for SLC22A6 (IC 50 of 14.0 M versus a K m of 147 M). These results suggest that raltegravir is a more efficient SLC22A6 inhibitor than it is a substrate. Previous studies indicated that SLC22A6 and SLC15A1 are absent from PBMCs (5), and so these transporters are unlikely to explain the unusual PK-PD relationship for raltegravir. Indeed, our studies of PBMCs with known inhibitors of ABCB1, SLC22A6, and SLC15A1 revealed no significant interaction with raltegravir.
Wenning et al. (38) previously studied the interaction of raltegravir (400 mg twice daily) and tenofovir (300 mg once daily). The study showed increased raltegravir AUC (49%) and C max (64%) values but no effect on the raltegravir C min and a decrease in the tenofovir AUC (10%), C max (23%), and C min (13%) (38) . SLC22A6 is expressed predominantly in the proximal tubule of the kidney on the basolateral (blood-facing) surface, thereby facilitating the removal of drugs out of the blood and into the urine (31) . Therefore, a possible mechanism of interaction is the inhibition of SLC22A6-mediated raltegravir transport at the kidney-proximal tubule by tenofovir, resulting in increased raltegravir plasma concentrations. In order to investigate interactions at the level of the kidney, we conducted a number of experiments with primary renal proximal cells. No interaction between tenofovir and raltegravir was observed for these cells, but neither was an interaction with the positivecontrol substrate and inhibitor. Subsequent analyses revealed the expression of SLC22A6 to be undetectable, unlike kidney tissue. Furthermore, all transporters that were assessed were at lower levels of expression than in kidney tissue, and the absence of a robust primary cell model for these studies is a limitation.
Since only a small percentage (around 30%) of raltegravir excreted via the kidney is in the parent form, with the remaining 70% being the glucuronide metabolite (24) , it is important to determine if the raltegravir glucuronide is also transported by SLC22A6 and inhibited by tenofovir. It would also be interesting to investigate the transport and inhibitory potential of tenofovir diphosphate for SLC22A6 and whether this affects raltegravir transport to the same degree.
The Xenopus laevis oocyte expression system has several advantages when investigating drug transport. The large size and high level of protein production of oocytes provide robust and reliable data. Also, the level of expression of endogenous primary and secondary active xenobiotic transporters in oocytes is low (32) . However, there are also disadvantages. The temperature must be maintained at 18°C during protein expression and at around room temperature during any accumulation experiments to avoid degradation, and this may impact transporter kinetics. Also, as in other models, the expression of the investigated transporters is superphysiological. Therefore, although they allow an investigation of low-affinity or highpermeability substrates, this means that caution should be taken when extrapolating the data to in vivo observations. In summary, our studies have shown raltegravir to have minimal interactions with known drug transporters. Raltegravir is transported by ABCB1 in vitro, although the rate of transport is low and the potential for interactions is expected to be small. Raltegravir is a substrate for SLC22A6 and SLC15A1 in X. Laevis oocyte expression systems and competes with tenofovir for SLC22A6 transport. Polymorphisms in SLC22A6 
